John Harvie

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Duncan Porter, Jurgen van Melckebeke, James Dale et al. · The Lancet · 2016 · 119 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +16

Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease—results of the Immune Metabolic Associations in Psoriatic Arthritis study

Lyn D Ferguson, Susanne Cathcart, Dominic Rimmer et al. · Lara D. Veeken · 2021 · 43 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Brief Report: Predicting Functional Disability: One‐Year Results From the Scottish Early Rheumatoid Arthritis Inception Cohort

Caroline Kronisch, David J. McLernon, James Dale et al. · Arthritis & Rheumatology · 2016 · 36 citations

Medicine, Clinical Sciences, Internal Medicine +17

Increased bone resorption in the critically ill: Association with sepsis and increased nitric oxide production

Lorna Smith, Brian H. Cuthbertson, John Harvie et al. · Critical Care Medicine · 2002 · 35 citations

Medicine, Orthopaedic Surgery, Bone Metabolism +16

The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank

James Dale, Caron Paterson, Ann Tierney et al. · BMC Musculoskeletal Disorders · 2016 · 31 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16